ABSTRACT -This overview of systematic reviews (SRs) aims to evaluate critically the evidence regarding the adverse effects of herbal medicines (HMs). 
Introduction
Herbal medicines (HMs) are popular in many countries, including the UK. 1, 2 The reasons for this widespread use are complex -see, for example, Ernst and Furnham (2000) 3 and Ernst (2008) 4 -but the assumption that 'natural' can be equated with 'safe' is certainly an important factor. 5 However, this notion is dangerously misleading: HMs contain pharmacologically active ingredients, some of which have been associated with adverse effects (AEs). [6] [7] [8] [9] The aim of this article is to provide an overview and critical evaluation of evidence from systematic reviews (SRs) of AEs associated with the use of HM products. It is important to remember that it does not attempt to identify or define all AEs of HM products: in many cases, probable AEs have been implicated but were not documented in an SR.
Methods
Electronic literature searches were conducted in January 2012 to identify SRs of AEs of HMs used in any type of clinical condition. The following electronic databases were used: Medline and Embase (via Ovid), the Allied and Complementary Medicine Database (AMED), CINHAL (via EBSCO) and the Cochrane database. Search terms were constructed using 'herbal medicine' and 'adverse events' terms and their derivatives, medical subject heading (MeSH) terms and 'review' in the title of the article (details of the search strategy are presented in the supplementary Appendix S1). In addition, our own extensive department files were searched by hand.
No restrictions on language or time of publication were imposed. Abstracts of reviews thus located were inspected and those that seemed to meet the inclusion criteria were retrieved for further evaluation by both authors. Systematic reviews were defined as articles that included an explicit and repeatable method. To be included, SRs had to pertain to AEs of HMs in human patients or volunteers. If multiple SRs were found for one specific HM, the most up-to-date, methodologically sound and independent review was chosen. Mixtures of more than one HM were excluded. Non-systematic reviews and reviews pertaining to the effectiveness of HMs were also excluded.
The quality of the methods underlying all SRs was assessed independently by the two reviewers using the modified Oxman score. 10, 11 This is a validated instrument that consists of the following domains for assessing the quality of the methods of review articles: reporting of search methods and their comprehensiveness, repeatable eligibility criteria, avoidance of selection bias and supportiveness of conclusions. We scored each of the above criteria as 1 (fulfilled), 0 (partially fulfilled) or -1 (not fulfilled). A final result of 0 or lower means the review has major flaws, of 1-2 means minor flaws and 3-5 means minimal or no flaws.
of drug interactions. [13] [14] [15] [16] [17] 21, 23, 27, [32] [33] [34] [35] [36] [37] [38] [39] [40] 45, 47, [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] The number of primary studies included in the SRs ranged from 1 38 to 216. 28 The types of primary reports varied from case studies to epidemiological investigations. Some SRs also included secondary analyses such as review articles. 15, 23, 45, 47, 51, 52, 59, 61 One SR employed a meta-analytical approach. 26 Thirty-one SRs concluded that the HM in question was safe. [13] [14] [15] [16] [17] [18] [19] [20] [21] [23] [24] [25] [26] 29, 31, 32, 35, 38, 39, [42] [43] [44] [45] 47, 50, 53, 55, [57] [58] [59] [60] Fifteen SRs reported moderately severe AEs, 12, 22, 27, 28, 30, 36, 40, 41, 46, 48, 49, 51, 52, 54, 56 and four SRs concluded that the HM in question was not safe (see Supplemental Tables S1 and S2) . 33, 34, 37, 61 Thirteen SRs mentioned the duration of AEs, 18, 20, 22, 24, 26, 28, 33, 42, [44] [45] [46] 48, 50 which ranged from 48 hours to 11 months. Forty-two SRs failed to mention conflict of interest of the authors. [13] [14] [15] [16] [17] [18] 22, 23, [25] [26] [27] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] Thirty-two SRs made no mention of any source of funding. [13] [14] [15] [16] [17] 22, 23, 27, 30, [34] [35] [36] [37] [38] [39] [40] [41] 44, 47, 48, [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] The quality of the methods of the included SRs was mixed (Table 1 
Results
The searches generated 4,366 potentially relevant titles and abstracts, of which 4,316 were excluded (Fig 1) . Fifty SRs met our inclusion criteria; 12-61 these originated from Canada, 21, 22 Denmark, 26 Germany, 17, 46 Italy, 19, 20, 62 South Africa, 41 the UK 12, 18, 24, 29 and the USA. 13-16,23.25,27,28,30-40,42-45,47,50-61 In these SRs, adverse effects of the following HMs were evaluated: Agave americana, 50 Aloe vera, 52 Boswellia serrata, 15 Calendula officinalis, 16 Camellia sinensis, 28 Capsaicin spp., 44 Cassia senna, 61 Caulophyllum thalictroides, 22 Cimicifuga racemosa, 48 Cinnamomum spp., 21 Cnicus benedictus, 53 Commifora mukul, 36 Crataegus spp., 20 Crocus sativus, 59 Curcuma longa, 43 Echinacea spp., 24 genus Phyllanthus, 26 Ginkgo biloba, 29 Gymnema sylvestre, 60 Harpagophytum procumbens, 17 Herbae pulvis standardisatus, 34 Hippocastanaceae, 32 Hoodia gordonii, 41 Hypericum perforatum, 45 Lagerstroemia speciosa, 38 Larrea tridentate, 33 Lavandula angustifolia Miller, 14 Melissa officinalis, 35 Mentha piperita, 51 Mentha spicata, 57 Morinda citrifolia, 42 Panax ginseng, 18 Pelargonium sidoides, 56 Perna canaliculus, 54 Petasites hybridus, 23 Piper methysticum, 37 Rosmarinus officinalis, 58 Salvia hispanica, 39 Serenoa repens, 12 Silybum marianum, 25 Stevia rebaudiana, 40 Taraxacum officinale, 30 Thymus vulgaris, 13 Trifolium pretense, 27 Trigonella foenum-graecum, 47 Vaccinium myrtillus, 55 Valeriana officinalis, 31 Viscum album 46 and Vitex agnus-castus. 19 Excluded: polyherbals (n= 667) and effectiveness reviews (n=2,376)
Excluded: none-SR (n=129) and non-independent (n=5)
Additional records identified through manual search (n=10)
Records screened (n =3,227)
Full-text articles assessed for eligibility (n =184) 37, 54 perinatal stroke, acute myocardial infarction, congestive heart failure, 54 severe multiorgan hypoxic injury, 22 carcinoma, 33, 61 perforation of the gastrointestinal tract, 61 seizures and epilepsy. 58 The large number of included SRs means that it is not easy to provide practical guidance through this labyrinth of HMs and multitude of AEs. Readers with an interest in one specific HM or one particular AE might look up the relevant SRs and refer to the primary reports. Readers with a more general interest in the safety of HMs would probably prefer to study those SRs that report serious AEs. 33, 34, 37, 61 The quality of the methods of some of the included SRs was frequently not optimal. This could be due to the fact that several of the articles were not designed as typical SRs. Many of the papers that scored poorly on quality were monograph-type publications, which are relatively frequent in the literature on HM. As these articles do nevertheless contribute relevant information, we decided to include them in our overview. Despite the fact that many SRs failed to achieve high-quality scores, we believe that virtually all of them contribute to our knowledge of AEs associated with HMs. In our view, none of the defects noted in Table 1 completely invalidates the SR in question. Even an SR that scored poorly on the formal quality rating can serve an important purpose when it alerts us to the risks associated with the HM in question.
Several challenges in methods and concepts were faced when undertaking this overview. We analysed data from SRs of AEs of specific HMs and omitted SRs of polyherbal preparations and effectiveness reviews (see Supplemental Table S3 ). [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] It was frequently impossible to differentiate between herb-drug interactions and AEs, as these questions were addressed simultaneously. Herb-drug interactions, adulteration and contamination obviously can also cause AEs. 1, [82] [83] [84] Our plan is to address these issues in specific analyses to be published as separate overviews.
This overview has further limitations that must be kept in mind when interpreting the evidence. Although a comprehensive search strategy was employed, there is no guarantee that all relevant SRs have been located. All SRs are prone to publication bias, and so any such bias may have been transferred to our overview. As we only included SRs, our overview cannot provide information on HMs for which no SR is available. A comprehensive review of all information available to date regarding AEs of HM would be a monumental task that by far exceeds the possibility of a single journal article. 85 The nature of the evidence reviewed here also requires a brief comment. Rigorous and comprehensive SRs of AEs should consider anecdotal data such as case reports. Such evidence is clearly relevant for assessing safety issues, but it does not lend itself to establishing cause and effect. We therefore ought to be cautious when interpreting such data and should critically question causality on a case-by-case basis.
In conclusion, numerous SRs of HMs have recently become available. Most of these SRs reveal mild adverse effects associated with HMs; however, some HMs might pose more severe health threats. 43 1 0 -1 -1 0 -1 *Scoring: each question is scored as 1, 0, or -1; a score of р0 means the review has major flaws, 1-2 means minor flaws and 3-5 means minimal or no flaws; 1 means that: (a) the review states the databases used, the date of the most recent searches and includes some mention of search terms; (b) the review searches at least two databases and looks at other sources; (c) the review states in the overview the criteria used for deciding which studies to include; (d) the review reports how many studies were identified by searches, the numbers of studies excluded and the appropriate reasons for excluding them; (e) the conclusions made by the author(s) are supported by the data and/or analysis reported in the review; 0 means that the above-mentioned criteria were partially fulfilled; and -1 means that none of the above criteria were fulfilled. This is an operationalisation of the Oxman criteria, 11 adapted from Ernst et al (2011). 10
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